Comments
Lupin has received approval for its Budesonide Inhalation Suspension, 0.5 mg/2 mL Single-Dose Ampules from the US Food and Drug Administration (FDA) to market a generic version of AstraZeneca Pharmaceuticals LP’s (AstraZeneca) Pulmicort Respules Inhalation Suspension. Budesonide Inhalation Suspension is indicated for the maintenance treatment of asthma and as prophylactic therapy in children 12 months to 8 years of age. Shares of Lupin closed at ₹853.15, down 0.85 per cent.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.